Are you confident taking a risk-based approach in managing type 2 diabetes as recommended by NICE?
Online Course
•
AstraZeneca
About the CPD course
An update to the NICE type 2 diabetes guidelines (NG28) has seen a paradigm shift in how type 2 diabetes (T2D) is managed. Blood glucose control is no longer recognised as the sole focus of T2D management; with the updated guideline recognising cardiovascular risk management as equally important. This 15-minute module walks you through: what first-line treatment is recommended in T2D; as recommended in the updated NICE guideline; how and when to assess cardiorenal risk and easily implement the NICE guideline into your practice; recognising which of your patients could benefit from sodium-glucose cotransporter-2 inhibitor (SGLT2i) treatment.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines.
Our Purpose is to push the boundaries of science to deliver life-changing medicines. We believe the best way we can achieve our Purpose is to put science at the centre of everything we do. Science defines who we are. It is why we come to work every day and is part of our DNA. But this is only half of the story. We know that we do not have all the answers. We want to share ideas because we believe it results in better medicines. We want the way we work to be inclusive, open and collaborative. This approach runs through all that we do.
